Table 3.
Antiviral efficacy results for F18 in combination with eight FDA-approved antiretroviral compounds against drug-resistant virus in PBMC assays
| Drug | Mean vol (effect) on virusa |
|||||
|---|---|---|---|---|---|---|
| NNRTI resistant |
NRTI resistant |
PI (SQV) resistant |
Multiresistant |
|||
| NVP resistant 181C | HIV-1IIIB A17, 103N/181C | AZT resistant, 41L/67N/69N/70R/215F/219Q | 3TC resistant, 184V | 48V/90 M | Δ67/69G/70R/74I/103N/215F/219Q | |
| NRTI | ||||||
| AZT | 502.94/−175.96 (highly synergistic) | 251.20/−82.10 (highly synergistic) | 316.43/−8.59 (highly synergistic) | 312.73/−105.60 (highly synergistic) | 2.43/−86.59 (additive) | 219.68/−152.19 (highly synergistic) |
| ddI | 595.13/0.00 (highly synergistic) | 126.80/−57.63 (highly synergistic) | 287.59/−102.88 (highly synergistic) | 665.78/−22.84 (highly synergistic) | 784.27/−41.37 (highly synergistic) | 542.96/−4.62 (highly synergistic) |
| d4T | 515.28/−150.56 (highly synergistic) | 267.79/−10.87 (slightly synergistic) | 8.70/−30.20 (additive) | 162.66/−184.84 (highly synergistic) | 209.30/−29.01 (highly synergistic) | 263.00/−281.44 (highly synergistic) |
| 3TC | 31.25/−229.93 (additive) | 130.45/−29.03 (highly synergistic) | 334.98/−138.74 (highly synergistic) | 339.17/−9.15 (highly synergistic) | 248.87/−30.61 (highly synergistic) | 289.70/−173.05 (highly synergistic) |
| NNRTI | ||||||
| NVP | 648.63/−14.76 (highly synergistic) | 173.14/−210.29 (highly synergistic) | 344.95/−94.52 (highly synergistic) | 212.14/−12.90 (highly synergistic) | 308.10/−11.27 (highly synergistic) | 289.52/−44.27 (highly synergistic) |
| EFV | 39.12/−64.89 (additive) | 78.93/−82.52 (highly synergistic) | 42.18/−6.82 (additive) | 50.98/−14.52 (additive) | 41.63/−12.94 (additive) | 742.48/−84.42 (highly synergistic) |
| PI | ||||||
| NFV | 0.60/−2.27 (additive) | 13.79/−0.89 (additive) | 288.95/−19.76 (highly synergistic) | 43.95/−6.32 (additive) | 37.01/−9.88 (additive) | 292.56/−47.33 (highly synergistic) |
| IN | ||||||
| RAL | 413.26/−148.00 (highly synergistic) | 52.12/−34.89 (additive) | 56.47/−9.78 (slightly synergistic) | 5.39/−0.13 (additive) | 43.24/−68.98 (additive) | 236.80/−25.89 (highly synergistic) |
a
Given as mean synergy volume/antagonist volume. Positive and negative values show synergistic and antagonistic interaction between F18 and other ARVs, respectively. SQV, saquinavir.